Table 3.
Outcomes of screening for 19 men in the BARCODE1 pilot study.
| Age, years | Pre‐biopsy PSA level, ng/mL | PI‐RADS Score pre‐biopsy MRI | Histology (Gleason score) | Management | Repeat MRI P‐IRADS Score | Repeat biopsy histology | Management | PRS |
|---|---|---|---|---|---|---|---|---|
| 62 | 0.78 | 4 | 3 + 3 | AS | 12.12 | |||
| 66 | 5.8 | 4 | 3 + 3 | AS | 11.19 | |||
| 66 | 2.3 | 3 | 3 + 3 | AS | 11.32 | |||
| 55 | 2.4 | 1 | 3 + 4 | AS | 2 | 3 + 3 | AS | 11.17 |
| 56 | 1 | 2 | 3 + 3 | AS | 11.53 | |||
| 64 | 3.6 | 4 | 3 + 3 | AS | 11.31 | |||
| 64 | 0.64 | 2 | ASAP | Repeat MRI and Bx at 6 months | 2 | 3 + 4 | AS | 11.42 |
| 55 | 0.35 | 2 | HGPIN | Repeat MRI and Bx at 6 months | 2 | Benign | Trial f/u | 11.32 |
| 56 | 2.6 | 2 | Benign | Trial f/u | 11.49 | |||
| 59 | 0.89 | 4 | Benign | Trial f/u | 11.38 | |||
| 60 | 0.46 | 3 | Benign | Trial f/u | 11.17 | |||
| 56 | 0.89 | 2 | Benign | Trial f/u | 11.69 | |||
| 56 | 0.3 | 2 | Benign | Trial f/u | 11.32 | |||
| 59 | 1.5 | 1 | Benign | Trial f/u | 11.53 | |||
| 60 | 0.93 | 3 | Benign | Trial f/u | 11.73 | |||
| 55 | 0.41 | 2 | Benign | Trial f/u | 12.21 | |||
| 66 | 1.7 | 2 | Benign | Trial f/u | 11.49 | |||
| 59 | 1.8 | 3 | Benign | Trial f/u | 11.44 |
Bx, biopsy; f/u, follow‐up.
Participant 4 underwent an MRI prostate and transperineal template biopsy as part of the local AS protocol and the Gleason score was downgraded on the second biopsy to 3 + 3. Patients 7 and 8 underwent a repeat MRI and biopsy as part of the pilot study, 6 months after initial biopsy due to findings of ASAP and HGPIN, respectively.